EP2013221B1 - Compositions and methods for cellular imaging and therapy - Google Patents

Compositions and methods for cellular imaging and therapy Download PDF

Info

Publication number
EP2013221B1
EP2013221B1 EP06769952.0A EP06769952A EP2013221B1 EP 2013221 B1 EP2013221 B1 EP 2013221B1 EP 06769952 A EP06769952 A EP 06769952A EP 2013221 B1 EP2013221 B1 EP 2013221B1
Authority
EP
European Patent Office
Prior art keywords
compound
tumor
targeting
imaging
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP06769952.0A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2013221A1 (en
EP2013221A4 (en
Inventor
David J. Yang
Chang Sok Oh
Dong-Fang Yu
Ali Azhdarinia
Saady Kohanim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of EP2013221A1 publication Critical patent/EP2013221A1/en
Publication of EP2013221A4 publication Critical patent/EP2013221A4/en
Application granted granted Critical
Publication of EP2013221B1 publication Critical patent/EP2013221B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • C07F13/005—Compounds without a metal-carbon linkage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
    • A61K51/0406—Amines, polyamines, e.g. spermine, spermidine, amino acids, (bis)guanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0493—Steroids, e.g. cholesterol, testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the present invention relates generally to the fields of chemistry and radionuclide imaging. More particularly, it concerns compositions and methods involving N4 compounds and derivatives.
  • Radionuclide imaging modalities Map the location and concentration of radionuclide-labeled compounds.
  • PET 18 F-fluorodeoxyglucose (FDG) has been used to diagnose and evaluate tumors, myocardial infarctions, and neurological diseases.
  • FDG F-fluorodeoxyglucose
  • tumor metabolic imaging using 18 F-FDG has been studied in the last two decades, its clinical practice is still limited by the factors such as easy access, availability and isotope cost.
  • 18 F chemistry is complex and requires longer synthesis times (e.g. 18 F-FDG, 40 min-75 min), and it is difficult to produce multiple agents simultaneously.
  • Radionuclide imaging modalities are diagnostic cross-sectional imaging techniques that map the location and concentration of radionuclide-labeled radiotracers.
  • CT and MRI provide considerable anatomic information about the location and the extent of tumors, these imaging modalities typically cannot adequately differentiate invasive lesions from edema, radiation necrosis, grading or gliosis.
  • PET and SPECT can be used to localize and characterize tumors by measuring metabolic activity. Thus methods that allow for more specific imaging of tumors is desirable.
  • EC ethylenedicysteine
  • EC ethylenedicysteine
  • Several compounds have been labeled with 99m Tc using nitrogen and sulfur chelates (Blondeau et al ., 1967; Davison et al ., 1980).
  • Bis-aminoethanethiol tetradentate ligands, also called diaminodithol compounds, are known to form very stable Tc(V)O complexes on the basis of efficient binding of the oxotechnetium group to two thiolsulfur and two amine nitrogen atoms.
  • Radiometal complexes of 2-pyrrolthiones labeled with 99m Tc-2-pyrrolthiones complexes have been developed for use as radiopharmaceuticals for imaging and therapy ( WO 0180906A2 ).
  • 99m Tc-L,L-ethylenedicysteine ( 99m Tc-EC) is a recent and successful example of N 2 S 2 chelates.
  • EC can be labeled with 99m Tc easily and efficiently with high radiochemical purity and stability, and is excreted through the kidney by active tubular transport (Surma et al ., 1994; Van Nerom et al ., 1990, 1993; Verbruggen et al ., 1990, 1992).
  • 99m Tc chelated with ethylenedicysteine (EC) and conjugated with a variety of ligands has been developed for use as an imaging agent for tissue-specific diseases, as a prognostic tool, and as a tool to deliver therapeutics to specific sites within a mammalian body ( WO 0191807A2 , AU 0175210A5 ).
  • 99m Tc-EC-chelates have been developed for renal imaging and examination of renal function ( U.S. Patent 5,986,074 and U.S. Patent 5,955,053 ).
  • a method of preparing 99m Tc-EC complexes and a kit for performing said method has also been developed ( U.S. Patent 5,268,163 and WO 9116076A1 ).
  • U.S. Patent 6,691,724 discloses ethylenecysteine drug conjugates.
  • the present invention presents compounds and methods relating to a simple chelation technique for labeling agents using metallic isotopes that may be used for tissue specific targeted radioimaging and radiotherapy.
  • the compound may be chelated to a metal atom.
  • Said metal atom may not be radioactive.
  • Said metal atom may be copper, cobalt, platinum, iron, arsenic, rhenium, or germanium.
  • Said compound may be chelated to a radionuclide.
  • Said radionuclide may be 99m Tc, 188 Re, 186 Re, 183 Sm, 166 Ho, 90 Y, 89 Sr, 67 Ga, 68 Ga, 111 In, 183 Gd, 59 Fe, 225 Ac, 212 Bi, 211 At, 45 Ti, 60 Cu, 61 Cu, 67 Cu, 64 Cu or 62 Cu.
  • said radionuclide is chosen from the group consisting of 68 Ga, 90 Y, 99m Tc, 68 Ga, or 188 Re. Said radionuclide may be 99m Tc.
  • the compound may be comprised in a pharmaceutical composition.
  • the subject may be a mammal, such as a human.
  • the compound may be chelated to 99m Tc, 188 Re, 186 Re, 183 Sm, 166 Ho, 90 Y, 89 Sr, 67 Ga, 68 Ga, 111 In, 183 Gd, 59 Fe, 225 Ac, 212 Bi, 211 At, 45 Ti, 60 Cu, 61 Cu, 67 Cu, 64 Cu or 62 Cu.
  • the compound may be administered in combination with a second anti-cancer compound, a radiation therapy, or surgery.
  • the subject may be a mammal, such as a human.
  • the compound may be chelated to 99m Tc, 188 Re, 186 Re, 183 Sm, 166 Ho, 90 Y, 89 Sr, 67 Ga, 68 Ga, 111 In, 183 Gd, 59 Fe, 225 Ac, 212 Bi, 211 At, 45 Ti, 60 Cu, 61 Cu, 67 Cu, 64 Cu or 62 Cu.
  • Said imaging may comprise PET imaging or SPET imaging.
  • kits comprising a compound of the present invention and a reducing agent.
  • the kit may comprise a radionuclide.
  • the radionuclide may be 99 m Tc, 188 Re, 186 Re, 183 Sm, 166 Ho, 90 Y, 89 Sr, 67 Ga, 68 Ga, 111 In, 183 Gd, 59 Fe, 225 Ac, 212 Bi, 211 At, 45 Ti, 60 Cu, 61 Cu, 67 Cu, 64 Cu or 62 Cu.
  • the kit may comprise an antioxidant (e.g., vitamin C, tocopherol, pyridoxine, thiamine, or rutin).
  • the kit may comprise a transition chelator (e.g., glucoheptonate, gluconate, glucarate, citrate, or tartarate).
  • the reducing agent may be tin (II) chloride or triphenylphosphine.
  • the words “comprising” (and any form of comprising, such as “comprise” and “comprises”), “having” (and any form of having, such as “have” and “has”), “including” (and any form of including, such as “includes” and “include”), or “containing” (and any form of containing, such as “contains” and “contain”) are inclusive or open-ended and do not exclude additional, unrecited elements or method steps.
  • radiotracers In the field of nuclear medicine, certain pathological conditions are localized, or their extent is assessed, by detecting the distribution of small quantities of internally-administered radioactively labeled tracer compounds (called radiotracers or radiopharmaceuticals). Methods for detecting these radiopharmaceuticals are known generally as imaging or radioimaging methods.
  • conjugate and “conjugated” is defined herein as chemically joining within the same molecule.
  • two or more molecules and/or atoms may be conjugated together via a covalent bond, forming a single molecule.
  • the two molecules may be conjugated to each other via a direct connection (e.g., where the compounds are directly attached via a covalent bond) or the compounds may be conjugared via an indirect connection (e.g., where the two compounds are covalently bonded to one or more linkers, forming a single molecule).
  • a metal atom may be conjugated to a molecule via a chelation interaction.
  • N4 derivative is defined herein as an N4 compound that has been conjugated to at least one other molecule or atom.
  • the derivative comprises a N4 compound that has an atom chelated to it.
  • the N4 derivative may comprise a N4 compound that is conjugated to a targeting ligand ( e.g. , via a covalent bond) and/or a linker (e.g., via a covalent bond) and/or a metal chelate (e.g., via a chelation interaction).
  • radioactive nuclide a species of atom able to exist for a measurable lifetime and distinguished by its charge, mass, number, and quantum state of the nucleus which, in specific embodiments, disintegrates with emission of corpuscular or electromagnetic radiation.
  • the term may be used interchangeably with the term “radioisotope”.
  • therapeutic agent as used herein is defined as an agent which provides treatment for a disease or medical condition.
  • the agent in a specific embodiment improves at least one symptom or parameter of the disease or medical condition.
  • the therapeutic agent reduces the size of the tumor, inhibits or prevents growth or metastases of the tumor, or eliminates the tumor.
  • a drug such as an anticancer drug, a gene therapy composition, a radionuclide, a hormone, a nutriceutical, or a combination thereof.
  • tumor as used herein is defined as an uncontrolled and progressive growth of cells in a tissue.
  • a skilled artisan is aware other synonymous terms exist, such as neoplasm or malignancy.
  • the tumor is a solid tumor.
  • the tumor derives, either primarily or as a metastatic form, from cancers such as of the liver, prostate, pancreas, head and neck, breast, brain, colon, adenoid, oral, skin, lung, testes, ovaries, cervix, endometrium, bladder, stomach, and epithelium.
  • drug as used herein is defined as a compound which aids in the treatment of disease or medical condition or which controls or improves any physiological or pathological condition associated with the disease or medical condition.
  • anticancer drug as used herein is defined as a drug for the treatment of cancer, such as for a solid tumor.
  • the anticancer drug preferably reduces the size of the tumor, inhibits or prevents growth or metastases of the tumor, and/or eliminates the tumor.
  • anticancer drug anti-cancer drug
  • anti-cancer compound are used interchangeably herein.
  • a or “an” may mean one or more.
  • the words “a” or “an” when used in conjunction with the word “comprising”, the words “a” or “an” may mean one or more than one.
  • another may mean at least a second or more.
  • N4 compounds which are typically hydrophobic chelators
  • hydrophobic molecules may be conjugated to hydrophobic molecules to produce novel compounds which may be used for purposes including imaging and radiotherapy.
  • Certain N4 compounds may be obtained from commercial source such as Sigma chemical company (St. Louis, MO) and Aldrich Chemical company (Milwaukee, WI).
  • U.S. Patent 5,880,281 describes a method for producing certain N4 compounds.
  • N4 compounds are defined herein as having the structure: wherein A 1 , A 2 , A 3 , and A 4 are alkyl; and wherein R 1 , R 2 , R 3 , and R 4 are hydrogen. Several N4 compounds are shown below.
  • N4 compounds can be used as chelators. For example, cyclam and other N4 compounds were tested for their ability to alleviate acute cadmium poisoning (Srivastava et al ., 1996).
  • U.S. Patent 4,141,654 describes certain compounds with structural similarity to N4 compounds that may be used to chelate actieride ions.
  • U.S. Patent 5,648,063 discloses compounds with structural similarity to N4 compounds which can chelate metal ions and may also be used in certain NMR diagnostic procedures.
  • U.S. Patent 6,071,490 utilizes a modified cyclen for PET imaging.
  • U.S. Patent 6,613,305 discloses Vitamin B 12 attached to various N4 compounds.
  • a targeting moiety e.g., a hydrophobic anticancer drug
  • a N4 compound that is not conjugated to a targeting moiety may be used for imaging and therapy.
  • a targeting moiety may be conjugated to the N4 compound via several methods. One method is to synthesize a halide (e.g., iodinated) targeting moiety. For example, the hydroxy group of a targeting moiety (e.g., a hydrophobic molecule) may be converted to a tosyl-, mesyl-, triflate or halide (e.g., iodine) group.
  • the reaction condition is typically performed in an organic solvent (dimethylformamide, DMF).
  • the final product is soluble in water after hydrochloride salt formation.
  • another method to conjugate N4 compound to a targeting moiety is to synthesize a sulfonate (e.g., tosyl- mesyl or triflate) targeting moiety.
  • Di-, tri- or all substitutes on the N4 compound may be prepared by reacting these iodinated or sulfonate targeting agents. For mono-substitutes, a selective protection of nitrogen groups is needed.
  • Targeting ligands that may be conjugated with an N4 compound include amino acids (e.g., tyrosine, serine), amino acid derivaitves (e.g., alphamethyltyrosine), tamoxifen, estrone, and tetraacetate mannose.
  • amino acids e.g., tyrosine, serine
  • amino acid derivaitves e.g., alphamethyltyrosine
  • tamoxifen e.g., estrone
  • estrone etraacetate mannose
  • ligands may also be conjugated to the N4 compound.
  • the ligands will possess either a halide or a hydroxy group that are able to react with and covalently bind to the N4 compound on either one or both acid arms.
  • Ligands contemplated include, but are not limited to, angiogenesis/antiangiogenesis ligands, DNA topoisomerase inhibitors, glycolysis markers, antimetabolite ligands, apoptosis/hypoxia ligands, DNA intercalators, receptor markers, peptides, nucleotides, antimicrobials such as antibiotics or antifungals, organ specific ligands and sugars, and agents that mimic glucose.
  • a targeting ligand that is known, or may be subsequently discovered, that possesses a hydroxy group or a halide, or alternatively may have a hydroxy group or halide introduced into its structure (e.g., via the addition of a sidechain, or by attaching a halide to a phenol group in the targeting ligand), may be used .
  • a targeting ligand may be directly conjugated to a N4 compound (e.g., via a covalent bond between the targeting ligand and the N4 compound), or a targeting ligand may be indirectly conjugated to a N4 compound via a linker.
  • targeting ligands that have previously been conjugated to another (non-N4 compound) chelator, such as EC, may be conjugated to N4 compounds and used for therapeutic purposes; in certain instances, it may be required to modify the targeting ligand (e.g., adding a side chain that contains a hydroxyl or a halide) in order to covalently bind the targeting ligand to the N4 compound.
  • covalent binding of ligands with EC compounds are typically performed in water, and in certain instances it may be preferred to covalently attach a targeting ligand with a N4 compound by utilizing a reaction in an organic solvent; in these instances, a targeting ligand that can be covalently bound to EC via a reaction in water may be modified (e.g., a halide or hydroxy group may be introduced to the structure) to allow the targeting ligand to be covalently bound to a N4 compound via a reaction in an organic solvent.
  • a targeting ligand that can be covalently bound to EC via a reaction in water may be modified (e.g., a halide or hydroxy group may be introduced to the structure) to allow the targeting ligand to be covalently bound to a N4 compound via a reaction in an organic solvent.
  • N4 derivatives may be used to target tumors (e.g., cancerous, precancerous, benign), tumor angiogenesis, hypoxia, apoptosis defects, disease receptors (e.g., cell receptors that are indicative of cancer), disease functional pathways (e.g., a metabolic pathway that has been altered by a disease state), and disease cell cycles. Additionally, N4 derivatives may be used for the assessment of a pharmaceutical agent's effectiveness on these biochemical processes.
  • N4 derivatives may also be used as a diagnostic tool and/or for predicting responses to certain kinds of treatment.
  • an N4 derivative that comprises tamoxifen an estrogen receptor targeting ligand
  • the imaging may provide important information about the disease such as to what degree the cancerous cells express the estrogen receptor which can be used to predict how the disease will respond to treatments that target cells expressing the estrogen receptor (e.g., when it is identified that cancerous tumors selectively express high levels of estrogen receptor, this information indicates that the cancerous cells will likely respond to therapeutic doses of anti-cancer agents that target cells expressing the estrogen receptor).
  • This approach is referred to as "image guided therapy”.
  • N4 derivatives used for imaging and/or therapy may comprise a N4 compound conjugated to a targeting ligands designed for targeting cancerous tumors, pre-cancerous tumors, disease receptors, hypoxic tissues (hypoxia), apoptosis pathways, disease cell cycles, and/or disease functional pathways.
  • N4 derivatives may also be used for assessing a pharmaceutical agent's effectiveness on various metabolic and/or biochemical pathways or individual reactions. Examples of certain targeting ligands which may be used the present invention can be found in Table 1.
  • an anti-cancer drug may be used as a targeting ligand.
  • Anti-cancer drugs are well known in the art (e.g., Connors,1996).
  • Table 2 in U.S. Patent 6,691,724 lists several examples of anti-cancer drugs which may be used as targeting ligands.
  • tumor angiogenesis targeting refers to the use of an agent to bind to tumor neovascularization and tumor cells. Agents that are used for this purpose are known to those of ordinary skill in the art for use in performing various tumor measurements, including measurement of the size of a tumor vascular bed, and measurement of tumor volume. Some of these agents bind to the vascular wall. One of ordinary skill in the art would be familiar with the agents that are available for use for this purpose.
  • a tumor angiogenesis targeting ligand is a ligand that is used for the purpose of tumor angiogenesis targeting as defined above. Examples of tumor angiogenesis targeting ligands include celecoxib, C225, herceptin, angiostatin, and thalidomide, which have been developed for the assessment of biochemical process on angiogenesis.
  • a tumor targeting ligand may associate with tumor tissues by targeting the hypoxia associated with tumor cells.
  • tumor targeting ligands that target hypoxic tissues include nitroimidazole and metronidazole, and these ligands may also be used to target other hypoxic tissues that are hypoxic due to a reason other than cancer (e.g., stroke).
  • Tumor apoptosis targeting refers to the use of an agent to bind to a cell that is undergoing apoptosis or is at risk of undergoing apoptosis. These agents are generally used to provide an indicator of the extent or risk of apoptosis, or programmed cell death, in a population of cells, such as a tumor. One of ordinary skill in the art would be familiar with agents that are used for this purpose. Certain examples of apoptosis targeting agents are shown in Table 1.
  • a "tumor apoptosis targeting ligand” is a ligand that is capable of performing "tumor apoptosis targeting” as defined in this paragraph.
  • Examples of a tumor apoptosis ligand includes a TRAIL (TNF-related apoptosis inducing ligand) monoclonal antibody.
  • TRAIL is a member of the tumor necrosis factor ligand family that rapidly induces apoptosis in a variety of transformed cell lines.
  • Other examples of tumor apoptosis targeting ligands include a substrate of caspase-3, such as peptide or polypeptide that includes the 4 amino acid sequence aspartic acid-glutamic acid-valine-aspartic acid.
  • disease receptor targeting certain agents are exploited for their ability to bind to certain cellular receptors that are overexpressed in disease states, such as cancer.
  • receptors which are targeted include estrogen receptors, amino acid transporters, androgen receptors, pituitary receptors, transferrin receptors, progesterone receptors, and glucose transporters.
  • agents that can be applied in disease-receptor targeting are shown in Table 1.
  • Disease receptor targeting ligands e.g ., pentetreotide, octreotide, transferrin, and pituitary peptide
  • Estrogen, estrone, and tamoxifen target the estrogen receptor.
  • Estrogen receptors are over expressed in certain kinds of cancer, and N4 derivatives that comprise an estrogen receptor targeting ligand may be used in certain embodiments to image tumors.
  • the expression of estrogen receptors is also altered in the diseases of osteoporosis and endometriosis. It is anticipated that an N4 derivative comprising an estrogen receptor targeting ligand may be used to image other diseases such as osteoporosis and endometriosis.
  • Glucose transporters are overexpressed in various diseased cells such as certain cancerous cells. Tetraacetate mannose, deoxyglucose, certain polysaccharides (e.g., neomycin, kanamycin, tobramycin), and monosaccharides (e.g., glucosamine) also bind the glucose transporter and may be used as disease receptor targeting ligands. Since these ligands are not immunogenic and are cleared quickly from the plasma, receptor imaging would seem to be more promising compared to antibody imaging.
  • polysaccharides e.g., neomycin, kanamycin, tobramycin
  • monosaccharides e.g., glucosamine
  • amino acid transporters are also overexpressed in various diseased cells such as certain cancerous cells.
  • Amino acids and/or amino acid derivatives e.g., serine, tyrosine, alpha methyltyrosine
  • Additional receptor targeting ligands are available and may be conjugated to N4 compounds.
  • Other examples of disease receptor targeting ligands include leuteinizing hormone and transferrin.
  • Folic acid, folate, tomudex, and methotrexate are examples of disease receptor targeting ligands that bind folate receptors.
  • Tumor targeting refers to the ability of a compound to preferentially associate with tumors (e.g ., cancerous, pre-cancerous, and/or benign).
  • a "tumor targeting ligand” refers to a compound which preferentially binds to or associates with tumor tissues, as compared to non-tumor tissues.
  • Ligands e.g., small molecules or antibodies which preferentially target tumors are well known in the art.
  • Disease cell cycle targeting refers to the targeting of agents that are upregulated in proliferating cells.
  • Compounds used for this purpose can be used to measure various parameters in cells, such as tumor cell DNA content.
  • Certain disease cell cycle targeting ligands are nucleoside analogues.
  • pyrimidine nucleoside e.g., 2'-fluoro-2'-deoxy-5-iodo-1-ß-D-arabinofuranosyluracil [FIAU], 2'-fluoro-2'-deoxy-5-iodo-1-ß-D-ribofuranosyl-uracil [FIRU], 2'-fluoro-2'-5-methyl-1-ß-D-arabinofuranosyluracil [FMAU], 2'-fluoro-2'-deoxy-5-iodovinyl-1-ß-D-ribofuranosyluracil [IVFRU]
  • acycloguanosine 9-[(2-hydroxy-1-(hydroxymethyl)ethoxy)methyl]guanine (GCV) and 9-[4-hydroxy-3-(hydroxy-methyl)butyl]guanine (PCV) (Tjuvajev et al ., 2002
  • disease targeting ligands include, for example, adenosine and penciclovir.
  • the antiviral nucleoside analog FHBG (a penciclovir analog), another disease targeting ligand, has for in vivo measurement of cell proliferation using PET (Alauddin et al ., 2001)
  • Disease cell hypoxia targeting refers to the targeting of agents that are upregulated in hypoxic cells.
  • Compounds used for this purpose can be used to measure various parameters in cells, such as tumor cell hypoxia, resistance or residual content.
  • Certain disease cell hypoxia targeting ligands include 2- or 5-nitroimidazole analogues.
  • 2- or 5-nitroimidazole analogues For example, misonidazole (2-nitroimidazole) and metronidazole (5-nitroimidazole) analogues.
  • Disease cell glycolysis targeting refers to the targeting of agents that are upregulated by glucose utilization in cells. Compounds used for this purpose can be used to measure various parameters in cells, such as tumor cell growth, inflammation degrees. Disease cell glycolysis targeting ligands include glucose, galactose, mannose and ribose analogues.
  • a desired ligand may still be conjugated to the N4 compound (which may or may not be radiolabeled) using the methods disclosed herein by adding a linker, such as ethylenediamine, amino propanol, diethylenetriamine, aspartic acid, polyaspartic acid, glutamic acid, polyglutamic acid, or lysine.
  • a linker such as ethylenediamine, amino propanol, diethylenetriamine, aspartic acid, polyaspartic acid, glutamic acid, polyglutamic acid, or lysine.
  • U.S. Patent 6,737,247 discloses several linkers which may be used .
  • U.S. Patent 5,605,672 discloses several "preferred backbones" which may be used as linkers.
  • an N4 compound may be conjugated to a linker, and the linker is conjugated to the targeting ligand.
  • more than one linker may be used; for example, an N4 compound may be conjugated to a linker, and the linker is conjugated to a second linker, wherein the second linker is conjugated to the targeting ligand.
  • two, three, four, or more linkers that are conjugated together may be used to conjugate an N4 compound and targeting ligand. However, it is generally preferable to only use a single linker to conjugate a N4 compound and a targeting ligand.
  • N4 derivative is defined herein as an N4 compound that has been conjugated to at least one other molecule or atom.
  • the derivative comprises a N4 compound that has an atom chelated to it.
  • the N4 derivative may comprise a N4 compound that is conjugated to a targeting ligand (e.g., via a covalent bond) and/or a linker (e.g., via a covalent bond) and/or a metal chelate ( e.g., via a chelation interaction).
  • an N4 derivative is a compound having the formula: wherein A 1 , A 2 , A 3 , and A 4 , are alkyl; and R 1 , R 2 , and R 3 are each independently chosen from the group consisting of: hydrogen, and wherein R 4 is chosen from the group consisting of: and
  • the N4 derivative may have a metal atom chelated to it (i.e., the N4 derivative may be labeled with a radioisotope).
  • the metal atom may be radioactive or non-radioactive.
  • a radioisotope may be chelated to the N4 derivative.
  • a N4 derivative may be conjugated (preferably chelated) to 99m Tc, 188 Re, 186 Re, 183 Sm, 166 Ho, 90 Y, 89 Sr, 67 Ga, 68 Ga, 111 In, 183 Gd, 59 Fe, 225 Ac, 212 Bi, 211 At, 45 Ti, 60 Cu, 61 Cu, 67 Cu, 64 Cu or 62 Cu.
  • Preferred ⁇ emitters include bismuth-213, astatine-211, and radium-223.
  • Preferred ⁇ , ⁇ -emitters include 166 Ho, 188 Re, 186 Re, 153 Sm, and 89 Sr.
  • Preferred ⁇ -emitters include 90 Y and 225 Ac.
  • Preferred ⁇ -emitters include 67 Ga, 68 Ga, 64 Cu, 62 Cu and 111 In.
  • Preferred ⁇ -emitters include 211 At and 212 Bi. It is also envisioned that paramagnetic substances, such as Gd, Mn, Cu or Fe can be chelated with N4 derivatives for use in conjunction with the present invention.
  • the radiolabel is typically a gamma-radiation emitting radionuclide and the radiotracer is typically located using a gamma-radiation detecting camera (this process is often referred to as gamma scintigraphy).
  • the imaged site is detectable because the radiotracer is chosen either to localize at a pathological site (termed positive contrast) or, alternatively, the radiotracer is chosen specifically not to localize at such pathological sites (termed negative contrast).
  • radionuclides are known to be useful for radioimaging and radioimmunotherapy, including 67 Ga/ 68 Ga, 99m Tc, 111 In, 123 I, 125 I, 169 Yb or 186 Re/ 188 Re. Due to better imaging characteristics and lower price, attempts have been made to replace or provide an alternative to 123 I, 131 I, 67 Ga and 111 In labeled compounds with corresponding 99m Tc labeled compounds when possible. Due to favorable physical characteristics as well as extremely low price ($0.21/mCi), 99m Tc is preferred to label radiopharmaceuticals.
  • Radionuclide that emits gamma energy in the 100 to 200 keV range is typically preferred.
  • the physical half-life of the radionuclide should be as short as the imaging procedure will allow.
  • 99m Tc is often a preferred radionuclide because it emits gamma radiation at 140 keV, it has a physical half-life of 6 hours, and it is readily available on-site using a molybdenum-99/technetium- 99m generator.
  • the N4 derivative may be labeled (e.g., chelated) with 68 Ga for PET imaging or 188 Re (a beta and gamma emitter) for internal radionuclide therapy.
  • 99m Tc, 68 Ga and 188 Re may be obtained from generators which are accessible and affordable.
  • non-radioactive metals e.g . copper, cobalt, platinum, iron, arsenic, rhenium, germanium
  • the cold (non-radioactive) N4 derivative may be used as a metallic chemotherapeutic agent.
  • One aspect of the uniqueness of this technology is to use the same PET sulfonate precursors or SPECT iodinated agents to react with a N4 compound which is a chelator.
  • the end product may then be chelated with metals which is easier, more accessible, and more affordable.
  • Technetium has a number of oxidation states: +1, +2, +4, +5, +6 and +7. When it is in the +1 oxidation state, it is called Tc MIBI. Tc MIBI is typically produced with a heat reaction (Seabold et al. 1999). For certain embodiments involving chelating Tc to a N4 compound or a N4 derivative, it is typically preferable that Tc is in the +4 oxidation state. This oxidation state is ideal for forming the chelate with a N4 compound or a N4 derivative. Thus, in forming a complex of radioactive technetium with the drug conjugates, the technetium complex, preferably a salt of 99m Tc pertechnetate, is typically reacted with the drug conjugates in the presence of a reducing agent.
  • the technetium complex preferably a salt of 99m Tc pertechnetate
  • the preferred reducing agent for use in the present invention is stannous ion in the form of stannous chloride (SnCl 2 ) to reduce the Tc to its +4 oxidation state.
  • stannous chloride SnCl 2
  • other reducing agents such as dithionate ion or ferrous ion may be useful in conjunction with the present invention.
  • the reducing agent may be a solid phase reducing agent.
  • the amount of reducing agent can be important as it is necessary to avoid the formation of a colloid. It is preferable, for example, to use from about 10 to about 100 ⁇ g SnCl 2 per about 100 to about 300 mCi of Tc pertechnetate. The most preferred amount is about 0.1 mg SnCl 2 per about 200 mCi of Tc pertechnetate and about 2 ml saline.
  • N4 derivatives labeled with radionuclides may also be used for imaging of tissue related to other diseases, as well as diagnostics related to cancer and other diseases.
  • the N4 derivatives labeled with radionuclides may be useful to image not only tumors, but also other tissue-specific conditions, such as infection, hypoxic tissue (stroke), myocardial infarction, apoptotic cells, Alzheimer's disease and endometriosis.
  • An advantage of imaging using a N4 derivative that comprises a radiolabeled N4 compound that is conjugated to a tissue targeting ligand is that the specific binding properties of the tissue targeting ligand concentrates the radioactive signal over the area of interest.
  • kits and means for preparing such complexes may be provided in a kit form that typically includes a sealed vial containing a predetermined quantity of a N4 derivative and a sufficient amount of reducing agent to label the conjugate with a radionuclide.
  • the kit includes a radionuclide.
  • the radionuclide is 99m Tc.
  • the kit may also contain conventional pharmaceutical adjunct materials such as, for example, pharmaceutically acceptable salts to adjust the osmotic pressure, buffers, preservatives, antioxidants, and the like.
  • an antioxidant and a transition chelator are included in the composition to prevent oxidation of the N4 derivative.
  • the antioxidant is vitamin C (ascorbic acid).
  • any other antioxidant known to those of ordinary skill in the art such as tocopherol, pyridoxine, thiamine, or rutin, may also be used.
  • transition chelators for use in the present invention include, but are not limited to, glucoheptonate, gluconate, glucarate, citrate, and tartarate.
  • the components of the kit may be in liquid, frozen or dry form. In certain embodiments, kit components may be provided in lyophilized form.
  • the N4 derivatives may also be used for prognostic purposes. It is envisioned that N4 derivatives may be administered to a patient having a tumor. It is envisioned that the use of a radiolabelled N4 compound as a labeling strategy can be effective with ligands designed for targeting disease receptors, hypoxia markers, apoptosis defects, disease cell cycles, disease functional pathways, and assessment of pharmaceutical agents effectiveness of these biochemical processes. Imaging may be performed to determine the effectiveness of the N4 derivative against a patient's specific problem relating to disease receptors, hypoxia markers, apoptosis defects, disease cell cycles, disease functional pathways, and assessment of pharmaceutical agent's effectiveness on these biochemical processes.
  • This methodology possesses significant advantages over methods involving first choosing a drug and administering a round of chemotherapy, which may involve months of the patient's time at a substantial physical and financial cost before the effectiveness of the cancer chemotherapeutic agent can be determined.
  • the present invention may also be used to monitor the progress of former patients who have sucessfully undergone chemotherapy or radiation treatment to determine if cancer has remained in remission or is metastasizing.
  • People with a history of cancer in their family or who have been diagnosed with a gene(s) associated with cancer may undergo monitoring by health professionals using the methodology of the current invention.
  • the methods and pharmaceutical agents of the current invention may also be used by a health professional to monitor if cancer has started to develop in a person with cancer risk factors, such as environmental exposure to carcinogens.
  • Certain drug-based ligands of the present invention can be applied in measuring the pharmacological response of a subject to a drug.
  • a wide range of parameters can be measured in determining the response of a subject to administration of a drug.
  • One of ordinary skill in the art would be familiar with the types of responses that can be measured. These responses depend in part upon various factors, including the particular drug that is being evaluated, the particular disease or condition for which the subject is being treated, and characteristics of the subject.
  • Radiolabeled agents can be applied in measuring drug assessment.
  • compositions of the present invention comprise an effective amount of an N4 derivative of the present invention dissolved or dispersed in a pharmaceutically acceptable carrier.
  • pharmaceutically acceptable refer to molecular entities and compositions that do not produce an adverse, allergic or other untoward reaction when administered to an animal, such as, for example, a human, as appropriate.
  • the preparation of a pharmaceutical composition that contains at least one N4 derivative, such as a radiolabeled N4 derivative, or additional active ingredient will be known to those of skill in the art in light of the present disclosure, as exemplified by Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990 .
  • preparations should meet sterility, pyrogenicity, general safety and purity standards as required by FDA Office of Biological Standards.
  • pharmaceutically acceptable carrier includes any and all solvents, dispersion media, coatings, surfactants, antioxidants, preservatives (e.g., antibacterial agents, antifungal agents), isotonic agents, absorption delaying agents, salts, preservatives, drugs, drug stabilizers, gels, binders, excipients, disintegration agents, lubricants, sweetening agents, flavoring agents, dyes, such like materials and combinations thereof, as would be known to one of ordinary skill in the art (see, for example, Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990, pp. 1289-1329 ). Except insofar as any conventional carrier is incompatible with the active ingredient, its use in the therapeutic or pharmaceutical compositions is contemplated.
  • the N4 derivatives of the present invention may comprise different types of carriers depending on whether it is to be administered in solid, liquid or aerosol form, and whether it needs to be sterile for such routes of administration such as injection.
  • the present invention can be administered intravenously, intradermally, intraarterially, intraperitoneally, intralesionally, intracranially, intraarticularly, intraprostaticaly, intrapleurally, intratracheally, intranasally, intravitreally, intravaginally, intrarectally, topically, intratumorally, intramuscularly, intraperitoneally, subcutaneously, subconjunctival, intravesicularlly, mucosally, intrapericardially, intraumbilically, intraocularally, orally, topically, locally, injection, infusion, continuous infusion, localized perfusion bathing target cells directly, via a catheter, via a lavage, in lipid compositions (e.g., liposomes), or by other method or any combination of the forgoing as would be known to one
  • the actual dosage amount of a composition of the present invention administered to a patient can be determined by physical and physiological factors such as body weight, severity of condition, the type of disease being treated, previous or concurrent therapeutic interventions, idiopathy of the patient and on the route of administration.
  • the practitioner responsible for administration will, in any event, determine the concentration of active ingredient(s) in a composition and appropriate dose(s) for the individual subject.
  • compositions may comprise, for example, at least about 0.1% of a N4 derivative.
  • the active compound may comprise between about 2% to about 75% of the weight of the unit, or between about 25% to about 60%, for example, and any range derivable therein.
  • a dose may also comprise from about 0.1 mg/kg/body weight, 0.5 mg/kg/ body weight, 1 mg/kg/body weight, about 5 mg/kg/body weight, about 10 mg/kg/body weight, about 20 mg/kg/body weight, about 30 mg/kg/body weight, about 40 mg/kg/body weight, about 50 mg/kg/body weight, about 75 mg/kg/body weight, about 100 mg/kg/body weight, about 200 mg/kg/body weight, about 350 mg/kg/body weight, about 500 mg/kg/body weight, about 750 mg/kg/body weight, to about 1000 mg/kg/body weight or more per administration, and any range derivable therein.
  • a derivable range from the numbers listed herein, a range of about 10 mg/kg/body weight to about 100 mg/kg/body weight, etc., can be administered, based on the numbers described above.
  • the composition may comprise various antioxidants to retard oxidation of one or more component.
  • the prevention of the action of microorganisms can be brought about by preservatives such as various antibacterial and antifungal agents, including, but not limited to parabens (e.g., methylparabens, propylparabens), chlorobutanol, phenol, sorbic acid, thimerosal or combinations thereof.
  • parabens e.g., methylparabens, propylparabens
  • chlorobutanol phenol
  • sorbic acid thimerosal or combinations thereof.
  • the N4 derivative may be formulated into a composition in a free base, neutral or salt form.
  • Pharmaceutically acceptable salts include the salts formed with the free carboxyl groups derived from inorganic bases such as for example, sodium, potassium, ammonium, calcium or ferric hydroxides; or such organic bases as isopropylamine, trimethylamine, histidine or procaine.
  • a carrier can be a solvent or dispersion medium comprising, but not limited to, water, ethanol, polyol (e.g., glycerol, propylene glycol, liquid polyethylene glycol, etc.), lipids (e.g., triglycerides, vegetable oils, liposomes) and combinations thereof.
  • the proper fluidity can be maintained, for example, by the use of a coating, such as lecithin; by the maintenance of the required particle size by dispersion in carriers such as, for example, liquid polyol or lipids; by the use of surfactants such as, for example, hydroxypropylcellulose; or combinations thereof such methods.
  • isotonic agents such as, for example, sugars, sodium chloride or combinations thereof.
  • Sterile injectable solutions are prepared by incorporating the N4 derivative in the required amount of the appropriate solvent with various amounts of the other ingredients enumerated above, as required, followed by filtered sterilization.
  • dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and/or the other ingredients.
  • the preferred methods of preparation are vacuum-drying or freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered liquid medium thereof.
  • the liquid medium should be suitably buffered if necessary and the liquid diluent first rendered isotonic prior to injection with sufficient saline or glucose.
  • the preparation of highly concentrated compositions for direct injection is also contemplated, where the use of DMSO as solvent is envisioned to result in extremely rapid penetration, delivering high concentrations of the active agents to a small area.
  • composition must be stable under the conditions of manufacture and storage, and preserved against the contaminating action of microorganisms, such as bacteria and fungi. It will be appreciated that endotoxin contamination should be kept minimally at a safe level, for example, less that 0.5 ng/mg protein.
  • prolonged absorption of an injectable composition can be brought about by the use in the compositions of agents delaying absorption, such as, for example, aluminum monostearate, gelatin or combinations thereof.
  • N4 derivatives such as a radiolabeled N4 derivative
  • the N4 derivative may precede or follow the other agent treatment by intervals ranging from minutes to weeks.
  • the other agent and expression construct are applied separately to the cell, one would generally ensure that a significant period of time did not expire between the time of each delivery, such that the agent and expression construct would still be able to exert an advantageously combined effect on the cell.
  • one may contact the cell, tissue or organism with two, three, four or more modalities substantially simultaneously (i.e., within less than about a minute) with the N4 derivative.
  • one or more agents may be administered within about 1 minute, about 5 minutes, about 10 minutes, about 20 minutes about 30 minutes, about 45 minutes, about 60 minutes, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours about 8 hours, about 9 hours, about 10 hours, about 11 hours, about 12 hours, about 13 hours, about 14 hours, about 15 hours, about 16 hours, about 17 hours, about 18 hours, about 19 hours, about 20 hours, about 21 hours, about 22 hours, about 23 hours, about 24 hours, about 25 hours, about 26 hours, about 27 hours, about 28 hours, about 29 hours, about 30 hours, about 31 hours, about 32 hours, about 33 hours, about 34 hours, about 35 hours, about 36 hours, about 37 hours, about 38 hours, about 39 hours, about 40 hours, about 41 hours, about 42 hours, about 43 hours, about 44 hours, about 45 hours, about 46 hours, about 47 hours, to about 48 hours or more prior to and/or after administering the N4 derivative.
  • an agent may be administered within of from about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 7 days, about 8 days, about 9 days, about 10 days, about 11 days, about 12 days, about 13 days, about 14 days, about 15 days, about 16 days, about 17 days, about 18 days, about 19 days, about 20, to about 21 days prior to and/or after administering the N4 derivative.
  • N4 derivative is "A” and the secondary agent, which can be any other therapeutic agent, is "B":
  • Administration of the therapeutic expression constructs of the present invention to a patient will follow general protocols for the administration of chemotherapeutics, taking into account the toxicity, if any, of the vector. It is expected that the treatment cycles would be repeated as necessary. It also is contemplated that various standard therapies, as well as surgical intervention, may be applied in combination with the N4 derivative. These therapies include but are not limited to chemotherapy, radiotherapy, immunotherapy, gene therapy and surgery.
  • Cancer therapies also include a variety of combination therapies with both chemical and radiation based treatments.
  • Combination chemotherapy include, for example, cisplatin (CDDP), carboplatin, procarbazine, mechlorethamine, cyclophosphamide, camptothecin, ifosfamide, melphalan, chlorambucil, busulfan, nitrosurea, dactinomycin, daunorubicin, doxorubicin, bleomycin, plicomycin, mitomycin, etoposide (VP16), tamoxifen, raloxifene, estrogen receptor binding agents, taxol, gemcitabien, navelbine, farnesyl-protein tansferase inhibitors, cisplatinum, 5-fluorouracil, vincristin, vinblastin and methotrexate, or any analog or derivative variant of the foregoing.
  • CDDP cisplatin
  • carboplatin carboplatin
  • DNA damaging factors include what are commonly known as ⁇ -rays, X-rays, and/or the directed delivery of radioisotopes to tumor cells.
  • Other forms of DNA damaging factors are also contemplated such as microwaves and UV-irradiation. It is most likely that all of these factors effect a broad range of damage on DNA, on the precursors of DNA, on the replication and repair of DNA, and on the assembly and maintenance of chromosomes.
  • Dosage ranges for X-rays range from daily doses of 50 to 200 roentgens for prolonged periods of time (3 to 4 wk), to single doses of 2000 to 6000 roentgens.
  • Dosage ranges for radioisotopes vary widely and depend on the half-life of the isotope, the strength and type of radiation emitted, and the uptake by the neoplastic cells.
  • the terms "contacted” and “exposed,” when applied to a cell, are used herein to describe the process by which a therapeutic construct and a chemotherapeutic or radiotherapeutic agent are delivered to a target cell or are placed in direct juxtaposition with the target cell. To achieve cell killing or stasis, both agents are delivered to a cell in a combined amount effective to kill the cell or prevent it from dividing.
  • Immunotherapeutics generally, rely on the use of immune effector cells and molecules to target and destroy cancer cells.
  • the immune effector may be, for example, an antibody specific for some marker on the surface of a tumor cell.
  • the antibody alone may serve as an effector of therapy or it may recruit other cells to actually effect cell killing.
  • the antibody also may be conjugated to a drug or toxin (chemotherapeutic, radionucleotide, ricin A chain, cholera toxin, pertussis toxin, etc.) and serve merely as a targeting agent.
  • the effector may be a lymphocyte carrying a surface molecule that interacts, either directly or indirectly, with a tumor cell target.
  • Various effector cells include cytotoxic T cells and NK cells.
  • Immunotherapy could thus be used as part of a combined therapy, possibly in conjunction with gene therapy.
  • the general approach for combined therapy is discussed below.
  • the tumor cell must bear some marker that is amenable to targeting, i.e ., is not present on the majority of other cells.
  • Common tumor markers include carcinoembryonic antigen, prostate specific antigen, urinary tumor associated antigen, fetal antigen, tyrosinase (p97), gp68, TAG-72, HMFG, Sialyl Lewis Antigen, MucA, MucB, PLAP, estrogen receptor, laminin receptor, erb B and p155.
  • the secondary treatment is a secondary gene therapy in which a therapeutic polynucleotide is administered before, after, or at the same time a first therapeutic agent. Delivery of the therapeutic agent in conjunction with a vector encoding a gene product will have a combined anti-hyperproliferative effect on target tissues.
  • Curative surgery is a cancer treatment that may be used in conjunction with other therapies, such as the treatment: disclosed herein chemotherapy, radiotherapy, hormonal therapy, gene therapy, immunotherapy and/or alternative therapies. Curative surgery includes resection in which all or part of cancerous tissue is physically or partially removed, excised, and/or destroyed. Tumor resection refers to physical removal of at least part of a tumor. In addition to tumor resection, treatment by surgery includes laser surgery, cryosurgery, electrosurgery, and miscopically controlled surgery (Mohs' surgery). It is further contemplated that the present invention may be used in conjunction with removal of superficial cancers, precancers, or incidental amounts of normal tissue.
  • 1,3,4,6-Tetra-O-acetyl-2-O-trifluoromethanesulfonyl-beta-D-mannopyranose 200 mg (0.416 mmol) put into the solution of cyclal 22.3mg (0.104 mmol) and triethyl amine 84.2 mg, 116 micromL(0.832mmol) in DMF(Anhydrous) 10mL. The mixture was stirred at 50°C for 16 hours under nitrogen atmosphere and evaporated to remove volatiles. The residue put into 1,4-dioxane 6mL, then white precipitate came out. The solid was thrown away through filtering. 1ml 4N-HCl in 1,4-dioxane solution was added drop by drop to filtrate solution, then pale brown powder precipitated. The solid was collected with filtering and dried under lyophilizer.
  • the solid was collected with filtering and dried under lyophilizer.
  • the solution was purified with membrane (MW cut off ⁇ 500), and evaporated under Lyophilizer. Pale brown solid 58.8mg(57.4% yield) was collected.
  • 1,3,4,6-Tetra-O-acetyl-2-O-trifluoromethanesulfonyl-beta-D-mannopyranose 200 mg (0.416 mmol) put into the solution of N,N',N"-tris (trifluoroacetyl)-cyclal(from Example 1, C) 209mg (0.416mmol) and triethyl amine 84.2mg, 116micromL (0.832mmol) in DMF (Anhydrous) 10mL. The mixture was stirred at 50°C for 6 hours under nitrogen atmosphere and evaporated to remove volatiles.
  • I-AMT 286.4mg(0.6mmol) put into the solution of cyclal 42.9mg(0.2mmol) and triethyl amine 83.6micrlL(0.6mmol) in DMF(Anhydrous) 10mL. The mixture was stirred at 70deg for 16hours under nitrogen atmosphere and evaporated to remove volatiles.
  • the mixture was stirred at 70deg for 6hours under nitrogen atmosphere and evaporated to remove volatiles.
  • 1N-potassium carbonate 2mL poured into the solution of evaporating residue in methanol 5ml and allowed to keep at 40deg for 1hour.
  • TsO-AMT sulfonated alpha methyltyrosine
  • 1,3,4,6-Tetra-O-acetyl-2-O-trifluoromethanesulfonyl-beta-D-mannopyranose 300 mg, 0.625 mmol
  • DMF 1,4,8,12-tetraazacyclopentacecane
  • N4 250.2 mg, 1.237 mmol
  • triethylamine 174 microL, 1.249 mmol
  • the reaction mixture was stirred at room temperature for 6 hrs.
  • the reaction solvent was evaporated to dryness at 40-45°C under high vacuum. 1,4-Dioxane solution (10 mL) was then added. The precipitate was filtered.
  • N4-DG (5mg) was dissolved in 0.2 ml water.
  • Tin(II) chloride solution (0.1 ml, 1mg/ml) was added.
  • Sodium pertechnetate Na 99m TcO 4 , 37-370 MBq, Mallinckrodt, Houston, TX was added.
  • water was added to this solution to adjust the volume to 1 ml.
  • Radiochemical purity was determined by TLC (ITLC SG, Gelman Sciences, Ann Arbor, MI) eluted with methanol : ammonium acetate (1:4). From radio-TLC analysis (Bioscan, Washington, DC), the radiochemical purity was more than 97%.
  • 68 Ga-labeling For 68 Ga-labeling, 68 Ga was eluted from a 68 Ge/ 68 Ga generator (Isotope Products Laboratories, Valencia, CA) using 1N HCL. The acidic solution was evaporated to dryness with either GaCl 3 carrier added or no carrier added. The soultion was reconstituted in water. N4-DG (5mg) dissolved in 0.2 ml water was then added to the radioactive solution.
  • Two different cancer cell lines (human lung NSCLC A549, breast 13762) were used for cellular uptake assays.
  • the cell lines were obtained from American Type Culture Collection (Rockville, MD). The cells were plated to 12 wells tissue culture plate that contained 50,000 per each well. 4 ⁇ Ci (0.148 MBq) of 99m Tc- and 68 Ga-N4-DG or N4 (0.1 mg/well) was added to each well. Cells were incubated with radiotracers at 37°C at different time intervals. After incubation, cells were washed with ice-cold phosphate-buffered saline (PBS) twice and trypsinized with 0.5 ml of trypsin solution. Then cells were collected and the radioactivity was measured by gamma counter. Data are expressed in mean ⁇ SD percent uptake ratio of three measurements.
  • PBS ice-cold phosphate-buffered saline
  • the injection activity was 25 ⁇ 0.5 ⁇ Ci (0.925 ⁇ 0.019 MBq)/rat.
  • the injected mass of 99m Tc-N4-DG was 0.1 mg/rodent.
  • the rats were sacrificed and the selected tissues were excised, weighed and counted for radioactivity. The biodistribution of tracer in each sample was calculated as percentage of the injected dose per gram of tissue wet weight (%ID/g). Tumor/nontarget tissue count density ratios were calculated from the corresponding %ID/g values.
  • mice Female Fischer 344 rats (150 ⁇ 25 g) (Harlan Sprague-Dawley, Indianapolis, IN) were inoculated subcutaneously with 0.1 ml of mammary tumor cells from the 13762 tumor cell line suspension (10 6 cells/rat, a tumor cell line specific to Fischer rats) into the hind legs. Imaging studies were performed 12 to 15 days after inoculation. Tumor sizes approximately 1-1.5 cm were measured. Scintigraphic images were obtained using a M-camera from Siemens Medical Systems (Hoffman Estates, IL). The camera was equipped with a low-energy parallel-hole collimator. The field of view is 53.3 cm x 38.7 cm.
  • the system is designed for a planar sensitivity of at least 172 counts/minute (cpm)/ ⁇ Ci and spatial resolution of 4-20 mm.
  • uPET was used for PET imaging studies (0.5 mCi/rat).
  • Planar scintigraphy was obtained at immediate, 0.5-4 hrs after i.v. injection of 99m Tc-N4-DG or 99m Tc-N4 (0.3 mCi/rat; 0.1mg mass/rabbit).
  • ROIs region of interest in counts per pixel
  • the ROIs count between tumor and muscle was used to calculate tumor-to-nontumor ratios.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
EP06769952.0A 2006-04-19 2006-05-04 Compositions and methods for cellular imaging and therapy Active EP2013221B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74514806P 2006-04-19 2006-04-19
PCT/US2006/016784 WO2007120153A1 (en) 2006-04-19 2006-05-04 Compositions and methods for cellular imaging and therapy

Publications (3)

Publication Number Publication Date
EP2013221A1 EP2013221A1 (en) 2009-01-14
EP2013221A4 EP2013221A4 (en) 2010-12-15
EP2013221B1 true EP2013221B1 (en) 2015-06-24

Family

ID=38609808

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06769952.0A Active EP2013221B1 (en) 2006-04-19 2006-05-04 Compositions and methods for cellular imaging and therapy

Country Status (13)

Country Link
EP (1) EP2013221B1 (no)
JP (1) JP2009534381A (no)
KR (2) KR101653182B1 (no)
CN (1) CN101516899B (no)
AU (1) AU2006342202C1 (no)
BR (1) BRPI0621580B8 (no)
CA (1) CA2649869C (no)
DK (1) DK2013221T3 (no)
ES (1) ES2544244T3 (no)
HK (1) HK1123306A1 (no)
IL (1) IL194826A (no)
NO (1) NO341574B1 (no)
WO (1) WO2007120153A1 (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8758723B2 (en) * 2006-04-19 2014-06-24 The Board Of Regents Of The University Of Texas System Compositions and methods for cellular imaging and therapy
CN101626787A (zh) * 2007-01-19 2010-01-13 马林克罗特公司 诊断的和治疗的环氧合酶-2结合配体
US9585841B2 (en) 2013-10-22 2017-03-07 Tyme, Inc. Tyrosine derivatives and compositions comprising them
JPWO2015152128A1 (ja) * 2014-03-31 2017-04-13 長瀬産業株式会社 アミノ酸前駆体、アミノ酸およびその製造方法、ならびに該アミノ酸を用いたｐｅｔ診断用トレーサー
GB201417067D0 (en) 2014-09-26 2014-11-12 South African Nuclear Energy Radiopharmaceutical conjugate
KR20190089191A (ko) * 2016-11-30 2019-07-30 타임, 인크. 티로신 유도체 및 이들을 포함하는 조성물
MX2020000673A (es) * 2017-07-18 2020-07-29 Vyripharm Entpr Llc Composiciones que contienen conjugados análogos de cannabinoides y métodos de uso.
US11090395B2 (en) * 2018-09-14 2021-08-17 SeeCure Taiwan Co., Ltd. Composition for cross talk between estrogen receptors and cannabinoid receptors
US11534420B2 (en) 2019-05-14 2022-12-27 Tyme, Inc. Compositions and methods for treating cancer
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections
US11554184B2 (en) 2021-03-26 2023-01-17 Vyripharm Enterprises, Inc. Synthetic cannabinoid combination therapy compositions and methods for personalized and targeted therapies including the treatment of infectious diseases
CN117088825A (zh) * 2023-10-12 2023-11-21 成都威斯津生物医药科技有限公司 一种可离子化脂质、含该可离子化脂质的药物组合物及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4988496A (en) * 1988-05-31 1991-01-29 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
US5650133A (en) * 1990-01-19 1997-07-22 Nycomed Salutar Macrocyclic polyaza dichelates linked through ring nitrogens via an amide or ester functionality
US5684149A (en) * 1993-01-22 1997-11-04 Research Foundation Of State University Of New York Metal complexes for promoting catalytic cleavage of RNA by transesterification
US6770261B2 (en) * 1995-06-02 2004-08-03 Research Corporation Technologies Magnetic resonance imaging agents for the detection of physiological agents
WO2000035887A2 (en) * 1998-12-18 2000-06-22 Du Pont Pharm Co Vitronectin receptor antagonist pharmaceuticals
US6673333B1 (en) * 2000-05-04 2004-01-06 Research Corporation Technologies, Inc. Functional MRI agents for cancer imaging
DE60104421T2 (de) * 2000-05-12 2005-09-22 University Hospital Prochelators von radiometall markierten molekülen
EP1322626B1 (en) * 2000-09-29 2008-11-05 Anormed Inc. Process for preparation of n-1 protected n ring nitrogen containing cyclic polyamines and products thereof
DE10135356C1 (de) * 2001-07-20 2003-04-17 Schering Ag Makrocyclische Metallkomplexe und deren Verwendung zur Herstellung von Konjugaten mit Biomolekülen
US20050255038A1 (en) * 2002-04-12 2005-11-17 A And D Bioscience, Inc. Conjugates comprising cancer cell specific ligands, a sugar and diagnostic agents and uses thereof
CA2512310C (en) * 2003-01-13 2012-09-25 Bracco Imaging S.P.A. Improved linkers for radiopharmaceutical compounds
BRPI0606395A2 (pt) * 2005-01-05 2009-06-23 Univ Texas conjugados para ambas imagem e radioquimioterapia: composição, fabricação e aplicações

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DAVID J YANG ET AL: "Targeting EGFR-TK with radiolabeled cyclam-tyrosine", AMERICAN ASSOCIATION FOR CANCER RESEARCH. PROCEEDINGS OF THE ANNUAL MEETING; 97TH ANNUAL MEETING OF THE AMERICAN-ASSOCIATION-FOR-CANCER-RESEARCH (AACR); WASHINGTON, DC, USA; APRIL 01 -05, 2006, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US; BIOSCIENCE, vol. 47, 1 April 2006 (2006-04-01), pages 2394, XP002691881, ISSN: 0197-016X *

Also Published As

Publication number Publication date
JP2009534381A (ja) 2009-09-24
AU2006342202B2 (en) 2013-03-07
EP2013221A1 (en) 2009-01-14
EP2013221A4 (en) 2010-12-15
ES2544244T3 (es) 2015-08-28
IL194826A0 (en) 2009-08-03
AU2006342202A1 (en) 2007-10-25
BRPI0621580B1 (pt) 2021-05-11
CN101516899A (zh) 2009-08-26
BRPI0621580B8 (pt) 2021-05-25
AU2006342202C1 (en) 2013-09-26
NO20084821L (no) 2009-01-16
HK1123306A1 (en) 2009-06-12
DK2013221T3 (en) 2015-09-28
BRPI0621580A2 (pt) 2011-05-10
CN101516899B (zh) 2016-07-06
WO2007120153A1 (en) 2007-10-25
CA2649869A1 (en) 2007-10-25
KR20140099557A (ko) 2014-08-12
KR20090014164A (ko) 2009-02-06
KR101653182B1 (ko) 2016-09-01
CA2649869C (en) 2014-11-18
NO341574B1 (no) 2017-12-04
IL194826A (en) 2013-08-29

Similar Documents

Publication Publication Date Title
EP2013221B1 (en) Compositions and methods for cellular imaging and therapy
AU2009200201B2 (en) Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
US9546186B2 (en) Non-invasive diagnostic agents of cancer and methods of diagnosing cancer, especially leukemia and lymphoma
US9408928B2 (en) Compositions for targeted imaging and therapy
ligan et al. 99mTc-ethylenedicysteine-folate: a new tumor imaging agent. Synthesis, labeling and evaluation in animals
US9050378B2 (en) N2S2 chelate-targeting ligand conjugates
WO2000043004A1 (en) 1,4,8,11-tetraazacyclotetradecane derivatives as radiodiganostic agents and their use in determining hypoxia and radioresistance of tumors
JP2022538478A (ja) 前立腺特異的膜抗原（ｐｓｍａ）リガンド及びその使用
US20030133872A1 (en) Radiopharmaceutical agent for the treatment of early stage cancer
US20110236308A1 (en) Aryl Bidentate Isonitriles and Their Uses

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20081118

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK YU

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SY

RIN1 Information on inventor provided before grant (corrected)

Inventor name: KOHANIM, SAADY

Inventor name: YU, DONG-FANG

Inventor name: AZHDARINIA, ALI

Inventor name: OH, CHANG, SOK

Inventor name: YANG, DAVID, J.

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1123306

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20101112

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20121031

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20140311

RIN1 Information on inventor provided before grant (corrected)

Inventor name: OH, CHANG, SOK

Inventor name: KOHANIM, SAADY

Inventor name: AZHDARINIA, ALI

Inventor name: YANG, DAVID, J.

Inventor name: YU, DONG-FANG

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 732844

Country of ref document: AT

Kind code of ref document: T

Effective date: 20150715

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: WAGNER + HELBIG PATENTANWAELTE CONSEILS EN PRO, CH

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602006045777

Country of ref document: DE

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2544244

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20150828

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20150922

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150624

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 732844

Country of ref document: AT

Kind code of ref document: T

Effective date: 20150624

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150624

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150925

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150924

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150624

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151026

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150624

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150624

Ref country code: RO

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150624

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150624

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151024

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150624

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602006045777

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1123306

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 11

26N No opposition filed

Effective date: 20160329

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20160531

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150624

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150624

Ref country code: LU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20160504

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 13

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150624

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20060504

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150624

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150624

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230522

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20240415

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20240326

Year of fee payment: 19

Ref country code: FR

Payment date: 20240328

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20240410

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20240402

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240326

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20240515

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20240602

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20240612

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20240411

Year of fee payment: 19

Ref country code: FI

Payment date: 20240514

Year of fee payment: 19